Zyprexa works, but may cause profound sedation, FDA staff says

An FDA official has issued a memo citing reports of excessive sedation in some patients who received a long-acting, injectable form of Zyprexa, Eli Lilly and Co.'s blockbuster schizophrenia drug. The Indianapolis-based drugmaker says the formulation offers advantages that outweigh safety concerns, which it says "are manageable with appropriate labeling and risk-minimization activities."

View Full Article in:

Wall Street Journal (free content), The · Indianapolis Star (tiered subscription model), The · Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC